Fosgemcitabine Palabenamide

Summary

Fosgemcitabine Palabenamide (CHEMBL3126004) is a phase-3 clinical-stage small molecule; indicated across 6 conditions including biliary tract disorder and exocrine pancreatic carcinoma.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• Indications: 6 conditions
• Clinical trials: 6
• Chemistry: 580.5 Da · C25H27F2N4O8P

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL3126004
Name	Fosgemcitabine Palabenamide
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	11169170
Molecular formula	C25H27F2N4O8P
Molecular weight	580.5
InChIKey	NHTKGYOMICWFQZ-KKQYNPQSSA-N

SMILES: C[C@@H](C(=O)OCC1=CC=CC=C1)NP(=O)(OC[C@@H]2[C@H](C([C@@H](O2)N3C=CC(=NC3=O)N)(F)F)O)OC4=CC=CC=C4

IUPAC name: benzyl (2S)-2-[[[(2R,3R,5R)-5-(4-amino-2-oxopyrimidin-1-yl)-4,4-difluoro-3-hydroxyoxolan-2-yl]methoxy-phenoxyphosphoryl]amino]propanoate

Also known as: Acelarin, BIO-1031, CPF-31, CPF31, Fosgemcitabine palabenamide, Fosgemcitabine palabenamide, p(rs)-, Gemictabine protide, Nuc-1031, NUC-1031, NUC-1031, (S)-, FOSGEMCITABINE PALABENAMIDE

Patent coverage: 111 distinct patent families (341 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

6 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
biliary tract disorder	3	MONDO:0004868	EFO:0009534
exocrine pancreatic carcinoma	2	MONDO:0005192	EFO:0002618
ovarian cancer	2	MONDO:0008170	MONDO:0008170
neoplasm	1	MONDO:0005070	EFO:0000616

2 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 6.

Phase distribution

Phase	Trials
PHASE1	3
PHASE2/PHASE3	1
PHASE3	1
PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT03610100	PHASE2/PHASE3	SUSPENDED	Acelarin First Line Randomised Pancreatic Study
NCT04163900	PHASE3	TERMINATED	Comparing NUC-1031 Plus Cisplatin to Gemcitabine Plus Cisplatin in Patients With Advanced Biliary Tract Cancer
NCT03146663	PHASE2	TERMINATED	NUC-1031 in Patients With Platinum-Resistant Ovarian Cancer
NCT01621854	PHASE1	COMPLETED	NUC-1031 in Patients With Advanced Solid Tumours
NCT02303912	PHASE1	COMPLETED	Safety and Efficacy Study of Nuc-1031 and Carboplatin Combination to Treat Recurrent Ovarian Cancer
NCT02351765	PHASE1	COMPLETED	ABC-08: Phase Ib Trial of Acelarin in Combination With Cisplatin in Locally Advanced/ Metastatic Biliary Tract Cancers

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).